OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA).

Under the terms of the MSA, OBI grants TegMine rights to utilize OBI’s GlycOBI^® ADC enabling technologies, powered by EndoSymeOBI^® and HYPrOBI^®, to identify ADC therapeutics candidates for potential clinical development. If an ADC product candidate(s) is ensued, OBI and TegMine would enter into a formal licensing agreement.

“This strategic collaboration leverages the synergistic strengths of both organizations,” noted Heidi Wang, Ph.D., OBI Pharma’s Chief Executive Officer. “In addition to advancing OBI’s compelling ADC products, we are focused on leveraging the innovative ADC enabling technologies, like GlycOBI^®, for strategic partnership. We look forward to working closely with TegMine to generate novel ADC candidates to treat patients with unmet medical need.”

“This collaboration reflects the exciting convergence of two innovative platforms,” said Jeff Bernstein, Ph.D., Chief Executive Officer of TegMine Therapeutics. “OBI’s ADC technology is an ideal complement to our efforts to target cancer-specific glycans. Together, we have the opportunity to develop ADCs with unprecedented tumor specificity and therapeutic impact.”